David F. Jarrard, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Urology|
Professional Certifications and Education
Urologic Oncology, Johns Hopkins Hospital, Baltimore, MD
University of Chicago Medical Center, Chicago, IL
University of Chicago Medical Center, Chicago, IL
University of Virginia School of Medicine, Charlottesville, VA, 1989
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.
Abel EJ Heckman JE Hinshaw L Best S Lubner M Jarrard DF Downs TM Nakada SY Lee FT Jr Huang W Ziemlewicz T .
Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. J Urol. 2015 Oct;194(4):886-91
[PubMed ID: 25837535]
Gee JR Saltzstein DR Messing E Kim K Kolesar J Huang W Havighurst TC Harris L Wollmer BW Jarrard D House M Parnes H Bailey HH .
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev. 2015 Aug 26;
[PubMed ID: 26313229]
Sweeney CJ Chen YH Carducci M Liu G Jarrard DF Eisenberger M Wong YN Hahn N Kohli M Cooney MM Dreicer R Vogelzang NJ Picus J Shevrin D Hussain M Garcia JA DiPaola RS .
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46
[PubMed ID: 26244877]
Blute ML Jr Abel EJ Downs TM Kelcz F Jarrard DF .
Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015 Aug;12(8):435-44
[PubMed ID: 26171803]
Blute ML Jr Rushmer TJ Shi F Fuller BJ Abel EJ Jarrard DF Downs TM .
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2015 Jul 11;
[PubMed ID: 26173101]
Yang B Damaschke N Yao T McCormick J Wagner J Jarrard D .
Pyrosequencing for accurate imprinted allele expression analysis. J Cell Biochem. 2015 Jul;116(7):1165-70
[PubMed ID: 25581900]
Blute ML Jr Damaschke NA Jarrard DF .
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol. 2015 Jan;25(1):83-8
[PubMed ID: 25405932]
Wagner J Damaschke N Yang B Truong M Guenther C McCormick J Huang W Jarrard D .
Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence. PLoS One. 2015;10(4):e0124366
[PubMed ID: 25876105]
Keil KP Abler LL Laporta J Altmann HM Yang B Jarrard DF Hernandez LL Vezina CM .
Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. Dev Biol. 2014 Dec 15;396(2):237-45
[PubMed ID: 25446526]
Jarrard DF Blute ML Jr Ritter MA .
Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J Clin Oncol. 2014 Dec 10;32(35):3926-9
[PubMed ID: 25332250]
Abel EJ Linder BJ Bauman TM Bauer RM Thompson RH Thapa P Devon ON Tarrell RF Frank I Jarrard DF Downs TM Boorjian SA .
Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014 Dec;66(6):1139-47
[PubMed ID: 25194909]
Damaschke NA Yang B Blute ML Jr Lin CP Huang W Jarrard DF .
Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. Neoplasia. 2014 Dec;16(12):1018-27
[PubMed ID: 25499215]
Abel EJ Bauman TM Weiker M Shi F Downs TM Jarrard DF Huang W .
Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Hum Pathol. 2014 May;45(5):1092-9
[PubMed ID: 24746216]
Abel EJ Wong K Sado M Leverson GE Patel SR Downs TM Jarrard DF .
Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS. 2014 Apr-Jun;18(2):282-7
[PubMed ID: 24960494]
Yang B Wagner J Damaschke N Yao T Wuerzberger-Davis SM Lee MH Svaren J Miyamoto S Jarrard DF .
A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLoS One. 2014;9(2):e88052
[PubMed ID: 24558376]
Truong M Slezak JA Lin CP Iremashvili V Sado M Razmaria AA Leverson G Soloway MS Eggener SE Abel EJ Downs TM Jarrard DF .
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15;119(22):3992-4002
[PubMed ID: 24006289]
Yang B Wagner J Yao T Damaschke N Jarrard DF .
Pyrosequencing for the rapid and efficient quantification of allele-specific expression. Epigenetics. 2013 Oct;8(10):1039-42
[PubMed ID: 23973940]
King AC Livermore A Laurila TA Huang W Jarrard DF .
Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol. 2013 Aug;31(6):739-43
[PubMed ID: 21816639]
Truong M Yang B Livermore A Wagner J Weeratunga P Huang W Dhir R Nelson J Lin DW Jarrard DF .
Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol. 2013 Jun;189(6):2335-41
[PubMed ID: 23159584]
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G .
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun;73(9):970-8
[PubMed ID: 23335089]